Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Beth A, Christian"'
Autor:
David A. Bond, Ying Huang, Beth A. Christian, Samantha Jaglowski, Don Benson, Lapo Alinari, Robert A. Baiocchi, Jonathon B. Cohen, Kristie A. Blum, Kami J. Maddocks
Publikováno v:
Leukemia & Lymphoma. 63:1750-1753
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7e2604e18b3b362d8147e751559167e
https://doi.org/10.1080/10428194.2022.2034154
https://doi.org/10.1080/10428194.2022.2034154
Autor:
Walter Hanel, Polina Shindiapina, David A. Bond, Yazeed Sawalha, Narendranath Epperla, Timothy Voorhees, Rina Li Welkie, Ying Huang, Gregory K. Behbehani, Xiaoli Zhang, Eric McLaughlin, Wing K. Chan, Jonathan E. Brammer, Samantha Jaglowski, John C. Reneau, Beth A. Christian, Basem M. William, Jonathon B. Cohen, Robert A. Baiocchi, Kami Maddocks, Kristie A. Blum, Lapo Alinari
Publikováno v:
Cancers
Volume 15
Issue 5
Pages: 1437
Volume 15
Issue 5
Pages: 1437
Background: Relapsed or refractory classical Hodgkin lymphoma (cHL) remains a difficult treatment challenge. Although checkpoint inhibitors (CPI) have provided clinical benefit for these patients, responses are generally not durable, and progression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2573fe5d1a45884763781762414b4c49
https://doi.org/10.3390/cancers15051437
https://doi.org/10.3390/cancers15051437
Autor:
Lisa Brown, Ann S. LaCasce, Linda Ho, Beth A. Christian, Chiyu Zhang, Nancy L. Bartlett, Ranjana H. Advani, Alex F. Herrera, Sahar Ansari, David R. Taft, Mariana Sacchi, Tatyana Feldman, Alison J. Moskowitz, Stephen M. Ansell, Julie M. Vose, Craig H. Moskowitz, Radhakrishnan Ramchandren
Publikováno v:
Blood. 138(6)
This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In parts 1 and 2, patients received staggered dosing of BV an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d15b0eafd5b59fffb7b5f819a434b4bc
https://pubmed.ncbi.nlm.nih.gov/34383039
https://pubmed.ncbi.nlm.nih.gov/34383039
Autor:
Arwa Shana'ah, Beth A. Christian, Jennifer A. Woyach, Kami J. Maddocks, Dan Jones, Narendranath Epperla, Sabarish Ayyappan
Publikováno v:
Blood Advances. 3:500-502
Ibrutinib is approved by the US Food and Drug Administration for the treatment of patients with relapsed/refractory marginal zone lymphoma (MZL) who are progressing on at least 1 previous anti-CD20–based therapy. This approval was based on the resu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36a9cb49680357d2b4a1c1c23be25ee0
https://doi.org/10.1182/bloodadvances.2018029058
https://doi.org/10.1182/bloodadvances.2018029058
Autor:
Kimberly Davies, Michael E. Williams, William Martin-Doyle, Jakub Svoboda, Zhengming Chen, Beth A. Christian, Catherine M. Bollard, Ann S. LaCasce, James Godfrey, Matthew J. Barth, Rebecca Gardner, Jody Sima, Matthew J. Oberley, Kristie A. Blum, Amanda M. Termuhlen, John P. Leonard, Tara O'Donohue, Sheila Weitzman, Zeinab Afify, Burton Appel, Christopher J. Forlenza, Hema Dave, Jennifer Levine, Carla Casulo, Deborah M. Stephens, Benjamin Mizukawa, Nancy L. Bartlett, Sonali M. Smith, Melinda Pauly, Sarah Alexander, Lisa Giulino-Roth, William A. Zeitler
Publikováno v:
British Journal of Haematology. 179:739-747
Summary Treatment with dose-adjusted EPOCH (etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone) chemotherapy and rituximab (DA-EPOCH-R) has become the standard of care for primary mediastinal B-cell lymphoma (PMBCL) at many institution
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5f7e95f98963ab8d14ef1ebb978bd9b
https://doi.org/10.1111/bjh.14951
https://doi.org/10.1111/bjh.14951
Autor:
Todd A. Fehniger, Steven M. Devine, Samantha Jaglowski, Nancy L. Bartlett, Lai Wei, Mitch A. Phelps, Beth A. Christian, Xiaohua Zhu, Jennifer Sexton, Joseph Maly, Nina D. Wagner-Johnston, Kristie A. Blum
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 17:347-353
Background Lenalidomide and panobinostat have shown single-agent efficacy of 14% to 50% and 27% to 58%, respectively, in Hodgkin lymphoma (HL). This phase I/II study was conducted to determine the maximum tolerated dose (MTD), safety, and efficacy of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b9f5fc499642ce6aecbbbbc2ce33ea7
https://doi.org/10.1016/j.clml.2017.05.008
https://doi.org/10.1016/j.clml.2017.05.008
Autor:
Ming Poi, Wenjun Ni, Flavia Pichiorri, Mitch A. Phelps, Jiang Wang, Douglas W. Sborov, Don M. Benson, Pierluigi Porcu, Craig C. Hofmeister, Joseph M. Flynn, Robert A. Baiocchi, Erinn M. Hade, Amir Mortazavi, Christopher C. Coss, Soun Khountham, Alessandro Canella, John C. Byrd, Xiaokui Mo, Leslie A. Andritsos, Beth A. Christian, Zhongfa Liu
Publikováno v:
Leukemia & Lymphoma. 58:2310-2318
Histone deacetylase inhibitors (HDACi) have proven activity in hematologic malignancies, and their FDA approval in multiple myeloma (MM) and T-cell lymphoma highlights the need for further development of this drug class. We investigated AR-42, an ora
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be4bfce3a5e0ab0d2340ced1b324cba9
https://doi.org/10.1080/10428194.2017.1298751
https://doi.org/10.1080/10428194.2017.1298751
Autor:
Arwa Shana'ah, Abner Louissaint, Berkman Sahiner, Robert P. Hasserjian, Beth A. Christian, Weijie Chen, Gerard Lozanski, Muhammad Khalid Khan Niazi, Metin N. Gurcan, Fazly Salleh Abas, Michael L. Pennell
Publikováno v:
Cytometry Part A. 91:609-621
The advance of high resolution digital scans of pathology slides allowed development of computer based image analysis algorithms that may help pathologists in IHC stains quantification. While very promising, these methods require further refinement b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cad609adaac71610cc8eac6c46246582
https://doi.org/10.1002/cyto.a.23049
https://doi.org/10.1002/cyto.a.23049
Autor:
William A. Wegener, Robert A. Baiocchi, Kristie A. Blum, Joseph M. Flynn, Mitch A. Phelps, Jeffrey A. Jones, Pierluigi Porcu, Don M. Benson, Lai Wei, Kami J. Maddocks, John C. Byrd, Beth A. Christian, Ming Poi, David M. Goldenberg
Publikováno v:
Br J Haematol
Summary As a result of the anti-tumour activity observed in vitro and in vivo with combined anti-CD20 and anti-CD74 antibodies, we initiated a phase I/II trial of veltuzumab and milatuzumab in patients with relapsed or refractory B-cell non-Hodgkin l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44215603ba1131c0b653fe49b57c0e9f
https://doi.org/10.1111/bjh.13354
https://doi.org/10.1111/bjh.13354
Autor:
Qiuhong Zhao, Lauren B. Levine, Leslie A. Andritsos, John C. Byrd, Jennifer A. Woyach, Anli McCoy, Tracy Wiczer, Nyla A. Heerema, Luay Mousa, Samantha Jaglowski, Beth A. Christian, Robert A. Baiocchi, Kami J. Maddocks, Amy S. Ruppert, Kerry A. Rogers, Avirup Guha, Steven M. Devine, Jeffrey A. Jones, Michael R. Grever, Kristie A. Blum, Farrukh T. Awan, Jessica Brumbaugh, Jessica Coggins
Publikováno v:
Blood advances. 1(20)
Atrial fibrillation (AF) has been reported in up to 16% of patients taking ibrutinib. Data regarding the management of AF in this patient population are limited, and stroke prevention poses a challenge because of increased risk of bleeding with ibrut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::328756bf08ec110e895f2c111c4442d4
https://pubmed.ncbi.nlm.nih.gov/29296820
https://pubmed.ncbi.nlm.nih.gov/29296820